IMI2 - Call 23
IMI2 - Call 23 was launched on 23 June 2020 with the following topics:
- Returning clinical trial data to study participants within a GDPR compliant and approved ethical framework
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
This topic is part of IMI’s Antimicrobial Resistance (AMR) Accelerator programme. - A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
- Optimal treatment for patients with solid tumours in Europe through artificial intelligence
- Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
- Behavioural model of factors affecting patient adherence
More information on the topics can be found in IMI's press release and in the Call text. Other relevant documents can be found on the IMI2 Call documents page.
Projects
The projects resulting from IMI2 - Call 23 are:
- BEAMER - Behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare
factsheet | website - EPND - European Platform for Neurodegenerative Diseases
factsheet | website - FACILITATE - Framework for clinical trial participants data reutilization for a fully transparent and ethical ecosystem
factsheet | website - OPTIMA - Optimal treatment for patients with solid tumours in Europe through artificial intelligence
factsheet | website - PRIMAVERA - Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
factsheet | website - SCREEN4CARE - Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies
factsheet | website
Call statistics
- Proposals submitted: 56
- Inadmissible & ineligible proposals: 2
- Proposals recommended for funding: 6
- Proposals not recommended for funding: 48